September 21, 2022 Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults with lupus nephritis, the kidney damage associated with lupus. The drug had also been approved this past January in the U.S. to treat adults with lupus nephritis in combination with a background immunosuppressive medication in […] READ MORE
September 21, 2022 Results of a small study published in the prestigious journal Nature Medicine, suggest that a type of immune cell therapy called chimeric antigen receptor (CAR) T cell therapy could become a highly effective therapy for SLE patients who do not respond to current lupus treatments. CD19 CAR T cells are T cells that […] READ MORE
September 7, 2022 The New York Jets 2022 football season kicked off last week with a spectacular luncheon that raised $740,000 for the Lupus Research Alliance and the New York Jets Foundation. The event also honored our former President and CEO Kenneth Farber for his years of commitment and progress in lupus research. Continuing as […] READ MORE
August 31, 2022 We are excited to share good news – our Lupus Clinical Investigators Network, LuCIN, managed by LRA’s affiliate Lupus Therapeutics, will be working on a new research project to increase diverse representation of patients in lupus trials to be funded with a $500,000 National Institutes of Health Innovation Award from the Food […] READ MORE
September 1, 2022 September 5 is designated by the United Nations as the International Day of Charity – created to mobilize people “to help others through volunteer and philanthropic activities.” Our mission at the Lupus Research Alliance is to transform the lives of people with lupus through the power of science, and this is an […] READ MORE
August 29, 2022 Big thanks go to the Lupus and Allied Diseases Association, Inc. (LADA) for their donation of $150,000 to support research funded by the Lupus Research Alliance given at their 22nd Annual Lupus Charity Golf Classic at Shenendoah Golf Course at Turning Stone in upstate New York. LADA President & CEO Kathleen A. […] READ MORE
NEW YORK, NY – August 24, 2022 – The Lupus Research Alliance (LRA) today announced its Global Team Science Award (GTSA) has been granted to three international research teams from 14 institutions across four continents comprised of leading experts spanning in immunology, rheumatology, neurosciences, biomedical engineering, genomics and genetics, and public health. With $3 million […] READ MORE
August, 2022 We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England Journal of Medicine showing that the investigational therapy litifilimab (BIIB059) lessened skin disease activity in cutaneous lupus erythematosus. There is a great unmet need for people with cutaneous lupus, a type of lupus with few treatment […] READ MORE
NUEVA YORK, NY. 10 de agosto de 2022. Lupus Research Alliance (LRA) se complace en anunciar el nombramiento de Albert Roy como presidente y director ejecutivo a partir del 6 de septiembre de 2022. El Sr. Roy actualmente se desempeña como director ejecutivo de Lupus Therapeutics, la filial que se encarga de los ensayos clínicos […] READ MORE
NEW YORK, NY. August 10, 2022 – The Lupus Research Alliance (LRA) is pleased to announce the appointment of Albert Roy to President and Chief Executive Officer effective September 6, 2022. Mr. Roy currently serves as Executive Director of Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance. He will succeed Kenneth M. […] READ MORE
August 4, 2022 Immunologists have found that a certain gut bacteria escapes from the intestines to trigger inflammation that can lead to autoimmune diseases. A new study published in Nature provides an insight into how particular gut bacteria evolve over time through a phenomenon called ‘within-host evolution’. The new findings open the door for the […] READ MORE
NEW YORK, NY. July 27, 2022. The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved belimumab (Benlysta®) as the first-ever treatment specifically indicated for children aged 5 to 17 with lupus nephritis. Belimumab is already approved by the FDA to treat lupus nephritis in adults […] READ MORE
